By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Sepracor Inc. et al. v. Dr. Reddy's Laboratories, Ltd. et al.
3:07-cv-05001; filed October 17, 2007 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 7,214,683 ("Compositions of Descarboethoxyloratadine," issued May 8, 2007) and 7,214,684 ("Methods for the Treatment of Allergic Rhinitis," issued May 8, 2007), licensed to Schering-Plough, following a paragraph IV certification as part of Dr. Reddy's filing of an ANDA to manufacture a generic version of Schering-Plough's Clarinex® (desloratidine, used to treat allergies). View the complaint here.
Teva Pharmaceutical Industries Ltd. et al. v. Zydus Pharmaceuticals, Inc. et al.
3:07-cv-04942; filed October 12, 2007 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 6,699,997 ("Carvedilol," issued March 2, 2004), 6,710,184 ("Crystalline Solids of Carvedilol and Processes for Their Preparation," issued March 23, 2004), 7,056,942 ("Carvedilol," issued June 6, 2006), and 7,126,008 (same title, issued October 24, 2006) based on Zydus' filing of an ANDA to manufacture and sell a generic version of GSK's Coreg® (carvedilol, used to treat congestive heart failure). View the complaint here.
Acorda Therapeutics, Inc. v. Apotex Inc. et al.
2:07-cv-04937; filed October 11, 2007 in the District Court of New Jersey
Infringement of U.S. Patent No. 6,455,557 ("Method of Reducing Somnolence in Patients Treated with Tizanidine," issued September 24, 2002) following a paragraph IV certification as part of Apotex's filing of an ANDA to manufacture a generic version of Acorda's Zanaflex Capsules (tizanidine hydrochloride capsules, used for the management of spasticity). View the complaint here.
Novartis Corporation et al. v. Mylan Laboratories Inc. et al.
2:07-cv-04918; filed October 11, 2007 in the District Court of New Jersey
Infringement of U.S. Patent No. 6,162,802 ("Synergistic Combination Therapy Using Benazepril and Amlodipine for the Treatment of Cardiovascular Disorders and Compositions Therefor," issued December 19, 2000) following a paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of Novartis' Lotrel® (amlodipine besylate/benazepril hydrochloride, used to treat hypertension). View the complaint here.
Comments